Hot Features
Premium
Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Aldeyra Therapeutics Inc | ALDX | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 3.935 | 03:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 3.935 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 1.42 - 11.97 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 3.935 | USD |
Aldeyra Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 231.46M | 58.90M | - | 0 | -37.54M | -0.64 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Aldeyra Therapeutics News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ALDX Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 3.96 | 4.18 | 3.79 | 3.92 | 453,110 | -0.025 | -0.63% |
| 1 Month | 3.32 | 4.97 | 3.1299 | 4.22 | 840,133 | 0.615 | 18.52% |
| 3 Months | 3.15 | 4.97 | 2.71 | 3.78 | 586,729 | 0.785 | 24.92% |
| 6 Months | 1.56 | 4.97 | 1.46 | 2.90 | 1,548,136 | 2.38 | 152.24% |
| 1 Year | 9.26 | 11.97 | 1.42 | 4.51 | 1,353,062 | -5.33 | -57.51% |
| 3 Years | 10.61 | 15.95 | 1.42 | 6.73 | 1,094,527 | -6.68 | -62.91% |
| 5 Years | 8.14 | 15.95 | 1.42 | 6.89 | 888,664 | -4.21 | -51.66% |
Aldeyra Therapeutics Description
| Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. |
